Rigel Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Rigel Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 43.3% bzw. 13% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 41.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 136.5% betragen.

Wichtige Informationen

43.3%

Wachstumsrate der Gewinne

41.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	13.0%
Zukünftige Eigenkapitalrendite	136.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	13 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Nov 08

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 10

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:RIGL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	226	38	39	N/A	6
12/31/2025	194	20	6	N/A	6
12/31/2024	169	9	N/A	N/A	6
9/30/2024	157	4	10	11	N/A
6/30/2024	130	-14	-13	-12	N/A
3/31/2024	119	-20	-7	-7	N/A
12/31/2023	116	-25	-21	-6	N/A
9/30/2023	129	-24	-36	-21	N/A
6/30/2023	121	-38	-49	-33	N/A
3/31/2023	125	-45	-67	-52	N/A
12/31/2022	116	-59	-74	-74	N/A
9/30/2022	86	-83	-71	-71	N/A
6/30/2022	87	-85	-68	-68	N/A
3/31/2022	77	-85	-1	0	N/A
12/31/2021	139	-18	5	6	N/A
9/30/2021	138	-15	8	9	N/A
6/30/2021	136	-8	-1	0	N/A
3/31/2021	131	-11	-70	-69	N/A
12/31/2020	109	-30	-53	-52	N/A
9/30/2020	106	-28	-48	-46	N/A
6/30/2020	108	-25	-43	-41	N/A
3/31/2020	102	-28	-46	-44	N/A
12/31/2019	59	-67	-43	-42	N/A
9/30/2019	82	-46	-21	-20	N/A
6/30/2019	66	-59	-26	-26	N/A
3/31/2019	57	-64	-37	-36	N/A
12/31/2018	45	-70	-60	-59	N/A
9/30/2018	7	-100	-91	-90	N/A
6/30/2018	3	-93	N/A	-88	N/A
3/31/2018	1	-87	N/A	-80	N/A
12/31/2017	4	-78	N/A	-78	N/A
9/30/2017	7	-68	N/A	-70	N/A
6/30/2017	10	-73	N/A	-75	N/A
3/31/2017	19	-67	N/A	-74	N/A
12/31/2016	20	-69	N/A	-76	N/A
9/30/2016	26	-66	N/A	-77	N/A
6/30/2016	35	-50	N/A	-64	N/A
3/31/2016	32	-51	N/A	-64	N/A
12/31/2015	29	-51	N/A	-23	N/A
9/30/2015	29	-61	N/A	-25	N/A
6/30/2015	16	-75	N/A	-34	N/A
3/31/2015	10	-87	N/A	-35	N/A
12/31/2014	8	-91	N/A	-70	N/A
9/30/2014	6	-85	N/A	-74	N/A
6/30/2014	6	-88	N/A	-76	N/A
3/31/2014	7	-86	N/A	-77	N/A
12/31/2013	7	-89	N/A	-86	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RIGLDas prognostizierte Gewinnwachstum (43.3% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: RIGLDie Erträge des Unternehmens (43.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).

Hohe Wachstumserträge: RIGLEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: RIGLDie Einnahmen des Unternehmens (13% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: RIGLDie Einnahmen des Unternehmens (13% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RIGLDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (136.5%).

Rigel Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.2% to US$28.67

Price target increased by 34% to US$26.75

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.43 loss

Price target increased by 44% to US$65.33

Consensus EPS estimates upgraded to US$0.65 loss

Recent updates

Price target increased by 7.2% to US$28.67

Now 68% overvalued after recent price rise

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Rigel Pharmaceuticals, Inc. Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Price target increased by 34% to US$26.75

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2024

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$0.43 loss

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Price target increased by 44% to US$65.33

Consensus EPS estimates upgraded to US$0.65 loss

Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application

Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress

Insufficient new directors

Consensus EPS estimates upgraded to US$0.062 loss

Consensus EPS estimates upgraded to US$0.073 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target increased by 14% to US$5.08

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Consensus EPS estimates fall by 13%

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

Consensus estimates of losses per share improve by 12%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date moved forward to 2025

Price target increased by 10% to US$4.46

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

President recently sold US$60k worth of stock

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

No longer forecast to breakeven

New minor risk - Share price stability

Forecast to breakeven in 2025

Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Consensus EPS estimates upgraded to US$0.19 loss

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial

Consensus EPS estimates upgraded to US$0.25 loss

New minor risk - Profitability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Price target increased by 7.6% to US$3.85

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

Rigel Pharmaceuticals, Inc. Announces Publication of REZLIDHIA (Olutasidenib) Phase 2 Clinical Results in Blood Advances

National Comprehensive Cancer Network Adds Newly Approved Rigel Pharmaceuticals, Inc.'s REZLIDHIA™ (Olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

Price target increased to US$4.11

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Rigel Pharmaceuticals, Inc. Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals, Inc. Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

Rigel Pharmaceuticals, Inc. Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals Received a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Rigel Pharmaceuticals, Inc. Announces Publication of Early Clinical Data of Olutasidenib in the Lancet Haematology

Third quarter 2022 earnings: EPS exceeds analyst expectations